CCK-58
| SMILES | None |
| InChIKey | None |
| Sequence | VSQRTDGESRAHLGALLARYIQQARKAPSGRMSIVKNLQNLDPSHRISDRDYMGWMDF |
Chemical properties
| Hydrogen bond acceptors | None |
| Hydrogen bond donors | None |
| Rotatable bonds | None |
| Molecular weight (Da) |
Drug properties
| Molecular type | Peptide |
| Endogenous/Surrogate | Endogenous |
| Approved drug | No |
Database connections
Bioactivities
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| Receptor | Activity | Source | |||||||
|---|---|---|---|---|---|---|---|---|---|
| GTP | Uniprot | Species | Family | Class | Type | Min | Avg | Max | Database |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.12 | 6.12 | 6.12 | ChEMBL |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.03 | 8.03 | 8.03 | Drug Central |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.4 | 9.4 | 9.4 | ChEMBL |
| S1P1 | S1PR1 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.754999999999999 | 9.75 | 9.75 | Guide to Pharmacology |
| S1P2 | S1PR2 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.4 | 8.4 | 8.4 | Drug Central |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.52 | 8.52 | 8.52 | Drug Central |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 5.3 | 5.3 | 5.3 | ChEMBL |
| S1P3 | S1PR3 | Human | Lysophospholipid (S1P) | A | pEC50 | 5.3 | 5.3 | 5.3 | Guide to Pharmacology |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.21 | 8.21 | 8.21 | Drug Central |
| S1P4 | S1PR4 | Human | Lysophospholipid (S1P) | A | pEC50 | 6.12 | 6.12 | 6.12 | Guide to Pharmacology |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 8.05 | 8.05 | 8.05 | Drug Central |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.01 | 9.01 | 9.01 | ChEMBL |
| S1P5 | S1PR5 | Human | Lysophospholipid (S1P) | A | pEC50 | 9.01 | 9.01 | 9.01 | Guide to Pharmacology |